These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23720229)

  • 1. High sensitive thyroglobulin assay on thyroxine therapy: can it avoid stimulation test in low and high risk differentiated thyroid carcinoma patients?
    Trimboli P; La Torre D; Ceriani L; Condorelli E; Laurenti O; Romanelli F; Ventura C; Signore A; Valabrega S; Giovanella L
    Horm Metab Res; 2013 Sep; 45(9):664-8. PubMed ID: 23720229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
    Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
    Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
    Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
    Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
    Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
    Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4 < 1 ng/ml determined by traditional assays?
    Rosario PW; Purisch S
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):338-42. PubMed ID: 17850379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
    Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
    Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
    J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases after differentiated thyroid carcinoma surgery.
    Makarewicz J; Adamczewski Z; Knapska-Kucharska M; Lewiński A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):485-9. PubMed ID: 17115345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitive 2nd generation thyroglobulin immunoradiometric assay. Clinical application in differentiated thyroid cancer management.
    Giovanella L; Ceriani L; Garancini S
    Q J Nucl Med; 2002 Dec; 46(4):319-22. PubMed ID: 12411872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?
    Flores-Rebollar A; Pérez-Díaz I; Lagunas-Bárcenas S; García-Martínez B; Rivera-Moscoso R; Fagundo-Sierra R
    Acta Otorhinolaryngol Ital; 2018 Jun; 38(3):188-193. PubMed ID: 29984794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer.
    Iervasi A; Iervasi G; Ferdeghini M; Solimeo C; Bottoni A; Rossi L; Colato C; Zucchelli GC
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):434-41. PubMed ID: 17555505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of efficacy of various methods of thyroglobulin measurements in differentiated thyroid cancer].
    Czernik E; Deja R; Gubała E; Kukulska A; Turska M; Dabrowska-Czuba E; Bartnikowa W; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():339-48. PubMed ID: 12182046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
    Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
    Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing?
    Díaz-Soto G; Puig-Domingo M; Martínez-Pino I; Martínez de Osaba MJ; Mora M; Rivera-Fillat F; Halperin I
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):348-52. PubMed ID: 21264807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer.
    Giovanella L; Ceriani L
    Clin Chem Lab Med; 2002 May; 40(5):480-4. PubMed ID: 12113292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.